Trial Profile

Phase II clinical study of radiotherapy combined with sintilimab and bevacizumab analogues (IBI305) in the treatment of advanced unresectable hepatocellular carcinoma with previous failure of immunotherapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2023 New trial record
24 Oct 2023 Status changed from not yet recruiting to recruiting, according to results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Preliminary results (n=10) assessing efficacy and safety of RT combined with PD-1 inhibitor (Sin) and antiangiogenic drug (Bev) in advanced HCC pts who had previously received PD-(L)1 inhibitors, presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com